Bristol Myers Squibb Partners with Microsoft for AI-Enabled Lung Cancer Diagnosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Strategic Partnership: Bristol Myers Squibb has partnered with Microsoft to leverage imaging technology used in 80% of U.S. hospitals, combining it with its oncology and drug delivery expertise to develop an AI-enabled workflow aimed at early lung cancer diagnosis, thereby enhancing medical efficiency and patient treatment outcomes.
- Market Potential: While this collaboration may seem small, its success could lay the groundwork for Bristol Myers Squibb to expand into other indications, further strengthening its competitive position in the pharmaceutical industry.
- Growth Metrics: Intuitive Surgical's da Vinci surgical robots saw a 13% increase in installations in 2025 compared to 2024, with a 19% rise in surgeries performed using these robots, indicating strong market demand for robotic surgery and signaling ongoing growth potential.
- Technological Innovation: Intuitive Surgical received FDA approval to integrate real-time AI imaging technology into its robots to address the challenges posed by lung movement during surgery, with the potential for fully automated AI surgeries in the future, further driving company growth.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 54.940
Low
37.00
Averages
55.86
High
68.00
Current: 54.940
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
